141 related articles for article (PubMed ID: 20083870)
21. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
Christiaens L; Ragot S; Mergy J; Allal J; Macchi L
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):235-9. PubMed ID: 18388505
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease.
Chadha DS; Sumana B; Karthikeyan G; Jayaprasad V; Arun SS
Catheter Cardiovasc Interv; 2016 Oct; 88(4):E126-E131. PubMed ID: 24482126
[TBL] [Abstract][Full Text] [Related]
23. Urinary 11-Dehydro-Thromboxane B
McCullough PA; Vasudevan A; Sathyamoorthy M; Schussler JM; Velasco CE; Lopez LR; Swift C; Peterson M; Bennett-Firmin J; Schiffmann R; Bottiglieri T
Am J Cardiol; 2017 Apr; 119(7):972-977. PubMed ID: 28139223
[TBL] [Abstract][Full Text] [Related]
24. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.
Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC
Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970
[TBL] [Abstract][Full Text] [Related]
25. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).
Blais N; Pharand C; Lordkipanidzé M; Sia YK; Merhi Y; Diodati JG
Thromb Haemost; 2009 Aug; 102(2):404-11. PubMed ID: 19652893
[TBL] [Abstract][Full Text] [Related]
26. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
[TBL] [Abstract][Full Text] [Related]
27. Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor.
Ikonomidis I; Andreotti F; Nihoyannopoulos P
Heart; 2004 Apr; 90(4):389-93. PubMed ID: 15020512
[TBL] [Abstract][Full Text] [Related]
28. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
[TBL] [Abstract][Full Text] [Related]
29. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.
Gao F; Wang ZX; Men JL; Ren J; Wei MX
Chin Med J (Engl); 2011 Jun; 124(11):1731-4. PubMed ID: 21740787
[TBL] [Abstract][Full Text] [Related]
30. Terms and conditions: semantic complexity and aspirin resistance.
Hennekens CH; Schror K; Weisman S; FitzGerald GA
Circulation; 2004 Sep; 110(12):1706-8. PubMed ID: 15381661
[No Abstract] [Full Text] [Related]
31. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Byrne A; Moran N; Maher M; Walsh N; Crean P; Fitzgerald DJ
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3224-9. PubMed ID: 9409315
[TBL] [Abstract][Full Text] [Related]
32. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
33. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
PLoS One; 2015; 10(5):e0126767. PubMed ID: 25993271
[TBL] [Abstract][Full Text] [Related]
34. Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery disease.
Vasudevan A; Bottiglieri T; Tecson KM; Sathyamoorthy M; Schussler JM; Velasco CE; Lopez LR; Swift C; Peterson M; Bennett-Firmin J; Schiffmann R; McCullough PA
Coron Artery Dis; 2017 Jun; 28(4):287-293. PubMed ID: 28005558
[TBL] [Abstract][Full Text] [Related]
35. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
[TBL] [Abstract][Full Text] [Related]
36. Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease.
Pi L; Che D; Long H; Fang Z; Li J; Lin S; Liu Y; Li M; Bao L; Li W; Zhang Y; Deng Q; Liu T; Zhang L; Gu X
Drug Des Devel Ther; 2018; 12():1353-1362. PubMed ID: 29872260
[TBL] [Abstract][Full Text] [Related]
37. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
Faraday N; Yanek LR; Mathias R; Herrera-Galeano JE; Vaidya D; Moy TF; Fallin MD; Wilson AF; Bray PF; Becker LC; Becker DM
Circulation; 2007 May; 115(19):2490-6. PubMed ID: 17470694
[TBL] [Abstract][Full Text] [Related]
38. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
Larsen SB; Grove EL; Kristensen SD; Hvas AM
Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
Yang M; Ye Z; Mei L; Ullah I; Tan C; Wang G; Gu Q; Lu Y; Abdus S; Shi L; Gong X; Bai J; Eikelboom JW; Li C
Eur J Clin Pharmacol; 2021 Dec; 77(12):1815-1823. PubMed ID: 34331551
[TBL] [Abstract][Full Text] [Related]
40. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
